Matthew Gall
Chief Financial Officer · 2 filings · Latest: May 1, 2026
Kalaris Therapeutics, Inc.
Tango Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
TNGX | Matthew Gall | Chief Financial Officer | May 1, 2026 | Grant/Award | $0.00 | 40,000 | — | 40,000 |